9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Safety Study of MGD009 in B7-H3-expressing Tumors

Condition Mesothelioma|Bladder Cancer|Melanoma|Squamous Cell Carcinoma of the Head and Neck|Non Small Cell Lung Cancer|Clear Cell Renal Cell Carcinoma|Ovarian Cancer|Thyroid Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer|Colon Cancer|Soft Tissue Sarcoma Estimated Enrollment: 114 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CP-MGD009-01 Study First Received: November 20, 2015 Last Updated: August 10, 2016 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: Number of participants with adverse events|Peak plasma concentration|Number of participants that develop anti-drug antibodies|Change in tumor volume Sponsors and Collaborators: MacroGenics Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02628535...

Continue reading

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Condition Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Malignant Rhabdoid Tumors (MRT)|Rhabdoid Tumors of the Kidney (RTK)|Atypical Teratoid Rhabdoid Tumors (ATRT)|Synovial Sarcoma|Epitheliod Sarcoma|Mesothelioma|Advanced Solid Tumors Estimated Enrollment: 300 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: EZH-501 Study First Received: August 5, 2016 Last Updated: September 13, 2016 Estimated Primary Completion Date: December 2023 Primary Outcome Measures: Long-term safety profile of tazemetostat measured by number of AEs and duration of exposure to tazemetostat|The overall survival (OS) Sponsors and Collaborators: Epizyme, Inc. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02875548...

Continue reading

CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Condition Solid Tumor|Advanced Cancer|ColoRectal Cancer|Endometrial Cancer|Gastric Cancer|Hepatocellular Cancer|Nonsmall Cell Lung Cancer|Mesothelioma|Ovarian Cancer|Renal Cancer|Nasopharyngeal Cancer|Esophageal Cancer|Gastroesophageal Junction Adenocarcinoma Estimated Enrollment: 50 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: CBT-501-01 Study First Received: January 30, 2017 Last Updated: March 30, 2017 Estimated Primary Completion Date: February 2018 Primary Outcome Measures: Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors|Determine the recommended Phase 2 dose and schedule|Area under the plasma concentration versus time curve (AUC)|Maximum plasma concentration|Time...

Continue reading

Cancer Research Repository for Individuals With Cancer Diagnosis, High Risk Individuals, and Individuals With No History of Cancer (Control)

Condition Pancreatic Cancer|Thyroid Cancer|Lung Cancer|Esophageal Cancer|Thymus Cancer|Colon Cancer|Rectal Cancer|GIST|Anal Cancer|Bile Duct Cancer|Duodenal Cancer|Gallbladder Cancer|Gastric Cancer|Liver Cancer|Small Intestine Cancer|Peritoneal Surface Malignancies|Familial Adenomatous Polyposis|Lynch Syndrome|Bladder Cancer|Kidney Cancer|Penile Cancer|Prostate Cancer|Testicular Cancer|Ureter Cancer|Urethral Cancer|Hypopharyngeal Cancer|Laryngeal Cancer|Lip Cancer|Oral Cavity Cancer|Nasopharyngeal Cancer|Oropharyngeal Cancer|Paranasal Sinus Cancer|Nasal Cavity Cancer|Salivary Gland Cancer|Skin Cancer|CNS Tumor|CNS Cancer|Mesothelioma|Breastcancer|Leukemia|Melanoma|Sarcoma|Unknown Primary Tumor|Multiple Myeloma|Ovarian Cancer|Endometrial Cancer|Vaginal Cancer Estimated Enrollment: 9999 Age Group: 19 Years to 110 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: UNMC 253-13 Study First Received: December 2, 2013 Last Updated: November 14, 2016 Estimated Primary Completion Date: December 2099 Primary Outcome Measures: Development and implementation of a web-based Cancer Collaborative Registry...

Continue reading

Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials

Condition Lymphoma|Thorasic Cancers|Prostate Cancer|Leukemia Estimated Enrollment: 360 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Control|Time Perspective: Cross-Sectional Study ID Numbers: 170010|17-CC-0010 Study First Received: October 27, 2016 Last Updated: April 21, 2017 Estimated Primary Completion Date: August 28, 2019 Primary Outcome Measures: Traumatic Stress Symptoms Sponsors and Collaborators: National Institutes of Health Clinical Center (CC) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02948413...

Continue reading

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Condition Malignant Mesothelioma|Pancreatic Cancer|Ovarian Tumor|Triple Negative Breast Cancer|Endometrial Cancer|Other Mesothelin Positive Tumors Estimated Enrollment: 20 Age Group: 18 Years to 70 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: s2015-080-06 Study First Received: October 19, 2015 Last Updated: October 19, 2015 Estimated Primary Completion Date: November 2017 Primary Outcome Measures: Occurrence of Study related adverse events|Anti-tumor responses to CART-meso cell infusions Sponsors and Collaborators: Chinese PLA General Hospital Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02580747...

Continue reading

Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue

Condition Thymus Tumors|Mesothelioma|Non- Small Cell Lung Cancer|Small Cell Lung Cancer Estimated Enrollment: 72 Age Group: 18 Years to 100 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: 130131|13-C-0131 Study First Received: May 8, 2013 Last Updated: April 21, 2017 Estimated Primary Completion Date: December 29, 2017 Primary Outcome Measures: Procurement of primary and metastatic tissue of thoracic malignancies shortly after death in order to investigate tumor heterogeneity- both intratumor and between paired primary and metastatic site, using integrated genomic and proteomic analysi...

Continue reading

Peritoneal Surface Malignancies – Characterization, Models and Treatment Strategies

Condition Pseudomyxoma Peritonei.|Colorectal Carcinoma.|Ovarian Carcinoma.|Mesothelioma. Estimated Enrollment: 200 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: PSM_250913 Study First Received: February 17, 2014 Last Updated: October 14, 2015 Estimated Primary Completion Date: January 2017 Primary Outcome Measures: Overall survival (OS)|Progression-free survival (PFS) Sponsors and Collaborators: Oslo University Hospital|The Research Council of Norway Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02073500...

Continue reading

Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

Condition Metastatic Colorectal Cancer Estimated Enrollment: 50 Age Group: 19 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 4-2015-0617 Study First Received: March 9, 2016 Last Updated: July 12, 2016 Estimated Primary Completion Date: July 2017 Primary Outcome Measures: Overall response rate|Progression-free survival|Overall survival|Disease control rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Sponsors and Collaborators: Yonsei University Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02723578...

Continue reading

Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma

Condition Malignant Tumor|Treatment Resistant Disorders|Tumor Progression Estimated Enrollment: 32 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: Eu-nr 2006-004076-13 Study First Received: October 8, 2013 Last Updated: October 8, 2013 Estimated Primary Completion Date: October 2016 Primary Outcome Measures: Maximal tolerable dose (phase I, ongoing)|Responses Sponsors and Collaborators: Karolinska University Hospital|Cancerfonden|Cancer and Allergy Foundation|Cancerföreningen i Stockholm|Stockholm County Council, Sweden Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01959438...

Continue reading